Related Experiment Video
Updated: Jun 26, 2026

High Throughput Quantitative Expression Screening and Purification Applied to Recombinant Disulfide-rich Venom Proteins Produced in E. coli
Published on: July 30, 2014
The application of toxins and venoms to cardiovascular drug discovery
Wayne C Hodgson1, Geoffrey K Isbister
1Monash Venom Group, Department of Pharmacology, Monash University, Victoria, Australia. wayne.hodgson@med.monash.edu.au
Abstract:
Animal venoms contain a variety of highly selective and potent toxins, which have evolved over thousands/millions of years, which target vital physiological processes. As such, they have proven to be an excellent source of lead compounds for the development of therapeutic agents. In particular, a number of these venom components (e.g. bradykinin-potentiating peptides, sarafotoxins, natriuretic peptides) have profound effects on the cardiovascular system. This review article examines recent progress in the search for lead compounds or novel scaffolds for cardiovascular drug development from animal venoms.
Related Concept Videos
Types of Toxins
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Pharmaceutical Poisoning: Treatment Strategies
Drug Discovery: Overview
Cardiovascular Drugs: Classification based on Therapeutic Indications
Drug Toxicity: Overview
Toxicity Testing in Animals

